Dexcom G6 Intervention Study

The study will assess if Continuous Glucose Monitoring (CGM) represents a better tool to
guide healthcare providers in adjusting insulin therapy, by providing a more complete 24-hour
assessment of glucose values compared to Point of Care (POC) testing, during hospitalization
and after hospital discharge in general medicine and surgery patients with T2D and T1D.

Inclusion Criteria:

1. Males and females ≥ 18 years admitted to a general medicine or surgical services.

2. History of T1D or T2D receiving insulin therapy during hospital admission.

3. Subjects must have a randomization BG between 140 mg and 400 mg/dL without laboratory
evidence of diabetic ketoacidosis (bicarbonate < 18 mEq/L, pH < 7.30, or positive
serum or urinary ketones).

4. Patients with expected hospital length-of-stay of 3 or more day

Exclusion Criteria:

1. Patients with acute illness admitted to the ICU or expected to require admission to
the ICU.

2. Patients expected to require MRI procedures during hospitalization.

3. Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and
portal hypertension), corticosteroid therapy, end-stage renal disease (dialysis), or
anasarca (massive peripheral edema).

4. Mental condition rendering the subject unable to understand the nature, scope, and
possible consequences of the study.

5. Female subjects who are pregnant or breast‑feeding at time of enrollment into the
study.